HOME >> MEDICINE >> NEWS
Infliximab could offer long-term benefits to people with Crohns disease

Sustained use of the drug infliximab could offer substantial clinical benefit to people with Crohns disease, conclude authors of a study in this weeks issue of THE LANCET.

Crohns disease is a chronic inflammatory disorder of the intestines. Patients often have to be treated with steroids, which are associated with severe side-effects. Previous research has suggested that the drug infliximab could reduce disease symptoms in the short term; Stephen Hanauer and colleagues from the University of Chicago, USA, investigated whether treatment with infliximab every two months could be more effective in reducing the symptoms of Crohns disease in the longer term compared with a single infusion of the drug.

355 patients with severe Crohns disease from the USA, Europe, and Israel who responded within two weeks to an initial 5 mg/kg intravenous infusion of infliximab took part in the study. They were randomly assigned repeat infusions of placebo, repeat infusions of 5 mg/kg infliximab, or 10 mg/kg infliximab (after two treatments with 5mg/kg infliximab). Treatment took place at randomisation, after one month, and thereafter every two months for a year.

More than twice as many people given infliximab every two months were in remission after 30 weeks compared with patients who only received initial infliximab treatment followed by placebo. Patients given sustained infliximab responded for longer (for 38 and 54 weeks for 5mg/kg and 10mg/kg regimens, respectively) compared with patients given placebo (who only responded to treatment for an average of 19 weeks). Patients given infliximab were also more likely to discontinue use of steroids compared with those given placebo.

Stephen Hanauer comments: This study was important to demonstrate a sustained response to maintenance treatment with infliximab in Crohns disease, similar to the results with maintenance treatment for rheumatoid arthritis. After a series of inductive infusions at baseline, 2 and
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7424-4949
Lancet
2-May-2002


Page: 1 2

Related medicine news :

1. Charcoal and forest management could reduce greenhouse gas levels & save lives in Africa
2. Novel therapy tested in mice could chase away cat allergies
3. Costs of antidepressants could have funded effective alternatives
4. Emergency clopidogrel could save thousands of lives46,000-patient heart attack trial results
5. Blood pressure treatment could cut risk of strokes and heart attacks
6. Proteins found in urine of pregnant women could help diagnose preeclampsia
7. Three out of the four million newborn babies who die each year could be saved
8. Increasing physician volume requirement could improve mammogram accuracy, study concludes
9. Chemicals in apples could reduce the risk of breast cancer, Cornell study in rats suggests
10. Training could remove racial bias from police reactions
11. Test could improve detection of prion disease in humans

Post Your Comments:
(Date:12/22/2014)... CA (PRWEB) December 22, 2014 The ... PALS, BLS and ACLS online certification provider, are proud ... http://www.acls-pals-bls.com . The updated site now features a more ... than ever to use. , As a company ... information is now consolidated into a single page during ...
(Date:12/22/2014)... 22, 2014 The holidays are here, and ... season. Many may be thinking about how to enjoy these ... few weeks. Health Republic Insurance of New York has compiled ... Chernus, to provide some smart ideas to enjoy the holiday ... 1)    Avoid arriving at a holiday gathering over-hungry , Have a ...
(Date:12/22/2014)... 19, 2014 (HealthDay News) -- U.S. and state health ... apples that has killed at least four people and ... not eat any commercially produced, prepackaged caramel apples until ... Control and Prevention said in a news release. ... had been infected with the outbreak strains of the ...
(Date:12/22/2014)... Physicians in China are most eagerly awaiting a ... lymphoma (NHL), according to a new report from ... MabThera is the only biologic available to treat diffuse ... NHL. , According to Kantar Health’s report, “Biosimilars in ... in China has been growing and is expected to ...
(Date:12/22/2014)... 22, 2014 Super Saturday, the last ... year as the busiest day in the 2014 holiday ... Grass Station had a steady pre-Christmas stream of customers, ... past Saturday. , “I definitely intend to take advantage…of ... Denver resident who was enjoying The Grass Station’s holiday ...
Breaking Medicine News(10 mins):Health News:ACLS Online Certification Website ACLS-PALS-BLS.com Now Features a New and User-Friendly Layout 2Health News:Health Republic Insurance of New York Offers Five Simple Tips to Eat Healthy During the Holidays 2Health News:CDC Warns of Listeria Danger From Caramel Apples 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2
(Date:12/22/2014)... and STOCKHOLM , Dec. 22, 2014 ... partner Auxilium Pharmaceuticals, Inc. today announced that the Committee ... European Medicines Agency (EMA) has adopted a positive opinion ... the treatment of adult men with Peyronie,s disease with ... 30 degrees at the start of therapy. ...
(Date:12/22/2014)... Dec. 22, 2014  Relmada Therapeutics, Inc. (OTCQB: ... the treatment of chronic pain, announced today that ... in a pharmacokinetic and pharmacodynamic study with d-Methadone, ... pain. Racemic methadone is a long-acting ... states and substitution therapy in opioid addiction.  It ...
(Date:12/19/2014)... -- You,re visiting the dentist for what you think ... she says you need a root canal. Though it,s ... several questions and feel apprehensive about your upcoming procedure. ... to worry about. The Pennsylvania Dental Association (PDA) wants ... the public may have surrounding this common procedure that ...
Breaking Medicine Technology:Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3Root Canals Have Become More Routine 2
Cached News: